Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 macrophages (Mϕ) play a key role in host antitumor defenses in HCC. In our study, CD14+ cells were isolated from the peripheral blood of four groups of HCC patients (group-1, patients with stage 0 HCC; group-2, patients with stage A HCC; group-3, patients with stage B HCC; and group-4, patients with stage C HCC) and characterized phenotypically. Then, CD14+ cells from group-2 and group-3 HCC patients were induced to polarize and tested for their antitumor abilities in a chimera model of HCC patients. Human HCCs (HepG2 solid tumors) grew in a chimera model of group-3 patients (group-3 HCC chimeras) but not in a chimera model of group-2 patients (group-2 HCC chimeras). In response to HCC antigens, the majority of CD14+ cells from group-2 patients (group-2 CD14+ cells) switched to the M1 phenotype (IL-12+IL-10-iNOS+cells), whereas the majority of CD14+ cells from group-3 patients (group-3 CD14+ cells) did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12-IL-10+CCL1+iNOS-cells). Group-3 CD14+ cells showed M1Mϕ polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of group-3 HCC chimeras are improved after CCL1 antisense ODN treatment.
Keywords: Antisense oligodexynuclotide; CCL1; hepatocellular carcinoma; host antitumor resistance; macrophage.